CN1330765C - 聚阳离子水溶性共聚物和将聚阴离子大分子跨生物屏障传递的方法 - Google Patents
聚阳离子水溶性共聚物和将聚阴离子大分子跨生物屏障传递的方法 Download PDFInfo
- Publication number
- CN1330765C CN1330765C CNB02827640XA CN02827640A CN1330765C CN 1330765 C CN1330765 C CN 1330765C CN B02827640X A CNB02827640X A CN B02827640XA CN 02827640 A CN02827640 A CN 02827640A CN 1330765 C CN1330765 C CN 1330765C
- Authority
- CN
- China
- Prior art keywords
- carrier
- polycationic polymer
- cell
- peg
- pei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/05—Polymer mixtures characterised by other features containing polymer components which can react with one another
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
Abstract
Description
共聚物 | N(GFLG) | W(PEI) | Mw | DNA/寡聚物结合 | 转染psDNA | 转染寡聚物 |
PEG-15PA-PEI400 | 0.0 | 2,344(10%) | 23,444 | + | - | - |
PEG-15PA-PEI800 | 0.0 | 8,400(30%) | 28,400 | + | + | + |
PEG-8PA-PEI800 | 0.0 | 2,607(11.5%) | 22,607 | + | - | + |
PEG-10PA-PEI1200 | 0.0 | 4,963(20.0%) | 24,936 | + | + | + |
PEG-8PA-PEI2K | 0.0 | 7,490(27%) | 27,490 | + | + | + |
PEG-15PA-GFLG-PEI400 | 9.0 | 2,000(7.8% | 25,400 | - | - | - |
PEG-15PA-GFLG-PEI800 | 9.0 | 4,400(15.8%) | 27,900 | + | + | + |
PEG-8PA-GFLG-PEI400 | 3.8 | 1,087(4.8%) | 22,577 | + | - | + |
PEG-8PA-GFLG-PEI800 | 3.8 | 2.207(9.3%) | 23,697 | + | + | + |
PEG-8PA-GFLG-PEI2K | 3.8 | 4,975(18,8%) | 26,465 | + | + | + |
对照: | ||||||
PEI-25K(购自Sigma) | 25,000 | + | + | + | ||
PEI-2K(购自Polysciences) | 1,800 | + | - | + | ||
PEI-400(购自Sigma) | 400 | - | - | - |
Claims (19)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/996,507 | 2001-11-28 | ||
US09/996,507 US7060498B1 (en) | 2001-11-28 | 2001-11-28 | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1617928A CN1617928A (zh) | 2005-05-18 |
CN1330765C true CN1330765C (zh) | 2007-08-08 |
Family
ID=25542997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB02827640XA Expired - Fee Related CN1330765C (zh) | 2001-11-28 | 2002-06-26 | 聚阳离子水溶性共聚物和将聚阴离子大分子跨生物屏障传递的方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7060498B1 (zh) |
EP (1) | EP1461436A4 (zh) |
JP (1) | JP2005510572A (zh) |
CN (1) | CN1330765C (zh) |
AU (1) | AU2002345981B2 (zh) |
CA (1) | CA2468548A1 (zh) |
HK (1) | HK1078103A1 (zh) |
MX (1) | MXPA04005194A (zh) |
WO (1) | WO2003046185A1 (zh) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
JP5610659B2 (ja) * | 2000-07-21 | 2014-10-22 | ルバンス セラピュティックス インク.Revance Therapeutics,Inc. | 多成分生物学的輸送システム |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
MXPA06009897A (es) * | 2004-03-03 | 2008-02-07 | Revance Therapeutics Inc | Composiciones y metodos para el diagnostico topico y el transporte terapeutico. |
NZ592041A (en) * | 2004-03-03 | 2012-12-21 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US20060040882A1 (en) | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
WO2005115457A2 (en) * | 2004-05-10 | 2005-12-08 | University Of Utah Research Foundation | Combined active and passive targeting of biologically active agents |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US8168222B2 (en) | 2004-09-07 | 2012-05-01 | Board Of Regents Of The University Of Nebraska | Amphiphilic polymer-protein conjugates and methods of use thereof |
US8017151B2 (en) * | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
KR100806601B1 (ko) * | 2004-09-17 | 2008-02-28 | 재단법인서울대학교산학협력재단 | 생분해성인 선형폴리에틸렌이민과 폴리에테르의 공중합체를 이용한 새로운 유전자 전달체 |
US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
CA2820728C (en) | 2004-12-22 | 2016-01-26 | Nitto Denko Corporation | Drug carrier and drug carrier kit for inhibiting fibrosis |
US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
JP5061349B2 (ja) * | 2005-02-10 | 2012-10-31 | 国立大学法人 東京大学 | ポリカチオン荷電性ポリマー及び核酸のキャリヤーとしての使用 |
BRPI0608091A2 (pt) * | 2005-03-03 | 2009-11-10 | Revance Therapeutics Inc | composições e processos para aplicação tópica e distribuição transdérmica de um oligopeptìdeo |
SG160357A1 (en) * | 2005-03-03 | 2010-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
WO2006098463A1 (ja) * | 2005-03-14 | 2006-09-21 | Shinka Soyaku Inc. | ポリ核酸結合物質 |
CN103126971A (zh) * | 2005-11-17 | 2013-06-05 | 雷文斯治疗公司 | 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法 |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
AU2007292219B2 (en) | 2006-09-06 | 2014-04-24 | The Regents Of The University Of California | Molecular diagnosis and classification of malignant melanoma |
US20100021502A1 (en) * | 2006-12-28 | 2010-01-28 | Waugh Jacob M | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT |
KR20090096735A (ko) * | 2006-12-29 | 2009-09-14 | 레반스 테라퓨틱스, 아이엔씨. | Hiv-tat로부터 유래된 폴리펩티드 단편에 의해 안정화된 보툴리눔 독소의 국소 적용 및 경피 전달용 조성물 및 방법 |
EP2109363A4 (en) * | 2006-12-29 | 2014-07-09 | Revance Therapeutics Inc | TRANSPORT MOLECULES USING HIV TAT POLYPEPTIDES WITH REVERSE SEQUENCE |
KR100825519B1 (ko) * | 2007-01-05 | 2008-04-25 | 주식회사 바이오폴리메드 | 키토산 기재 고분자 접합체 및 그 제조방법 |
TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
DK2494993T3 (en) | 2007-05-04 | 2018-11-12 | Marina Biotech Inc | Amino acid lipids and uses thereof |
KR102088949B1 (ko) * | 2007-07-26 | 2020-03-13 | 레반스 테라퓨틱스, 아이엔씨. | 항미생물 펩티드, 조성물, 및 이용 방법 |
ES2416719T3 (es) | 2007-08-13 | 2013-08-02 | Baxter International Inc. | Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson |
EP2207570A2 (en) | 2007-09-14 | 2010-07-21 | Nitto Denko Corporation | Drug carriers |
EP2212693B1 (en) | 2007-10-22 | 2015-04-22 | The Regents of The University of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
US8829109B2 (en) * | 2007-11-07 | 2014-09-09 | University Of Utah Research Foundation | Cleavable modifications to reducible poly(amido ethylenimine)s to enhance nucleotide delivery |
GB0723714D0 (en) * | 2007-12-04 | 2008-01-16 | Cambridge Entpr Ltd | Supramolecular handcuffs in polymeric architecture |
CA2716357A1 (en) | 2008-03-05 | 2009-09-11 | The Regents Of The University Of California | Molecular diagnosis and classification of malignant melanoma |
CN102027043A (zh) * | 2008-03-14 | 2011-04-20 | 艾根股份有限公司 | 生物可降解的交联支链聚(亚烷基亚胺) |
US8344116B2 (en) * | 2008-03-17 | 2013-01-01 | Case Western Reserve University | Polymers and complexes for delivery of nucleic acids to intracellular targets |
CN101298501B (zh) * | 2008-04-23 | 2011-08-24 | 武汉大学 | 含羧基类高分子纳米粒子及其制备方法和应用 |
EP2291544B1 (en) | 2008-05-16 | 2017-10-25 | The Children's Hospital of Philadelphia | Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes |
AU2009305639B2 (en) | 2008-10-16 | 2016-06-23 | Marina Biotech, Inc. | Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics |
NZ592905A (en) | 2008-10-27 | 2012-11-30 | Baxter Int | Models of thrombotic thrombocytopenic purpura and methods of use thereof |
US9271929B2 (en) * | 2008-11-25 | 2016-03-01 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
US20120016010A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 1 (BACH1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2408916A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害 |
AU2010229847A1 (en) | 2009-03-27 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA) |
US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CA2781896C (en) | 2009-12-09 | 2021-03-30 | Nitto Denko Corporation | Modulation of hsp47 expression |
CN102802655A (zh) | 2010-01-15 | 2012-11-28 | 康奈尔大学 | 降低细胞内蛋白质水平的方法 |
US20130137584A1 (en) | 2010-02-01 | 2013-05-30 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
SG186438A1 (en) | 2010-06-24 | 2013-01-30 | Quark Pharmaceuticals Inc | Double stranded rna compounds to rhoa and use thereof |
EP2601293B1 (en) | 2010-08-02 | 2017-12-06 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
KR102413007B1 (ko) | 2010-08-17 | 2022-06-24 | 시르나 쎄러퓨틱스 인코퍼레이티드 | 짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제 |
WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
US9233997B2 (en) | 2010-08-26 | 2016-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) |
AU2011312504B2 (en) | 2010-09-27 | 2016-12-22 | The Children's Hospital Of Philadelphia | Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease |
AU2011308567B2 (en) | 2010-10-01 | 2015-09-03 | Fundacion Centro Nacional De Investigaciones Oncologicas, Carlos Iii | Manipulation of stem cell function by p53 isoforms |
US20140134231A1 (en) | 2010-10-11 | 2014-05-15 | Sanford-Burnham Medical Research Institute | Mir-211 expression and related pathways in human melanoma |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
CN102154349B (zh) * | 2010-12-30 | 2014-08-06 | 江苏大学 | 阳离子化的桑叶多糖纳米粒基因载体及其制法 |
CN102154350B (zh) * | 2010-12-30 | 2012-08-29 | 江苏大学 | 阳离子化枸杞多糖纳米粒基因传递系统及其制法 |
BR112013020875A2 (pt) | 2011-02-15 | 2019-09-24 | Immune Design Corp | método para indução de uma resposta imune específica para um imunógeno em um indivíduo. |
JP6000287B2 (ja) | 2011-03-03 | 2016-09-28 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | 肺疾患および損傷を治療するための組成物および方法 |
CA2832307A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
EP2557089A2 (en) | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions and methods for immunomodulation |
ES2755782T3 (es) | 2011-07-26 | 2020-04-23 | Cambridge Entpr Ltd | Cápsulas supramoleculares |
RU2632462C2 (ru) | 2011-11-11 | 2017-10-05 | Фред Хатчинсон Кансэр Рисёч Сентер | Направленная на циклин a1 t-клеточная иммунотерапия рака |
WO2013106494A1 (en) | 2012-01-12 | 2013-07-18 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
EP2617434A1 (en) | 2012-01-20 | 2013-07-24 | Laboratorios Del. Dr. Esteve, S.A. | HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
GB201301648D0 (en) | 2013-01-30 | 2013-03-13 | Cambridge Entpr Ltd | Nested supramolecular capsules |
CN104245801B (zh) | 2012-02-20 | 2020-06-23 | 剑桥实业有限公司 | 基于葫芦脲的水凝胶 |
AU2013315524B2 (en) | 2012-09-12 | 2019-01-31 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
ES2872349T3 (es) | 2012-09-12 | 2021-11-02 | Quark Pharmaceuticals Inc | Moléculas de oligonucleótidos bicatenarios para DDIT4 y métodos de uso de las mismas |
MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
WO2015020960A1 (en) | 2013-08-09 | 2015-02-12 | Novartis Ag | Novel lncrna polynucleotides |
CA2939093A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
TWI662039B (zh) | 2014-05-13 | 2019-06-11 | 瑞士商諾華公司 | 用於誘發軟骨生成之化合物及組合物 |
AU2015260725B2 (en) | 2014-05-14 | 2021-02-25 | Targimmune Therapeutics Ag | Improved polyethyleneimine polyethyleneglycol vectors |
MX2017000630A (es) | 2014-07-15 | 2017-04-27 | Immune Design Corp | Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral. |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US10232050B1 (en) | 2014-12-12 | 2019-03-19 | Clemson University | Multi-functional particles and methods of using the same |
US11633355B2 (en) | 2014-12-12 | 2023-04-25 | Clemson University Research Foundation | Multi-functional particles and methods of using the same |
EP3292202A4 (en) | 2015-05-06 | 2019-04-10 | Benitec Biopharma Limited | REAGENTS FOR THE TREATMENT OF HEPATITIS B (VHB) VIRUS INFECTION AND USE THEREOF |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
CA3020754C (en) | 2016-04-14 | 2023-07-25 | Benitec Biopharma Limited | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
EP3269734A1 (en) | 2016-07-15 | 2018-01-17 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods and compositions for the treatment of cancer |
CN107432935A (zh) * | 2017-09-12 | 2017-12-05 | 四川大学 | 一种阳离子聚合物/TDNs载药复合物及其制备方法 |
EP3778628A4 (en) * | 2018-03-29 | 2021-11-24 | NOF Corporation | DEGRADABLE POLYETHYLENE GLYCOL CONJUGATE |
JP2022528020A (ja) | 2019-03-19 | 2022-06-07 | フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン | 癌の治療のための併用療法 |
EP3808763A1 (en) | 2019-10-17 | 2021-04-21 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for immunomodulation |
WO2023069979A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567410A (en) * | 1994-06-24 | 1996-10-22 | The General Hospital Corporation | Composotions and methods for radiographic imaging |
US5714166A (en) * | 1986-08-18 | 1998-02-03 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates |
US6221959B1 (en) * | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
YU45837B (sh) | 1988-01-18 | 1992-07-20 | LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. | Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom |
IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
US5380536A (en) | 1990-10-15 | 1995-01-10 | The Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
US5681747A (en) * | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
US6113946A (en) | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
ATE260679T1 (de) | 1992-04-03 | 2004-03-15 | Univ California | Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5777078A (en) * | 1993-04-28 | 1998-07-07 | Worcester Foundation For Experimental Biology | Triggered pore-forming agents |
US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
FR2739292B1 (fr) | 1995-09-28 | 1997-10-31 | Rhone Poulenc Rorer Sa | Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
DE19726186A1 (de) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
US6333051B1 (en) | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
-
2001
- 2001-11-28 US US09/996,507 patent/US7060498B1/en not_active Expired - Fee Related
-
2002
- 2002-06-26 EP EP02744728A patent/EP1461436A4/en not_active Withdrawn
- 2002-06-26 AU AU2002345981A patent/AU2002345981B2/en not_active Ceased
- 2002-06-26 CN CNB02827640XA patent/CN1330765C/zh not_active Expired - Fee Related
- 2002-06-26 JP JP2003547617A patent/JP2005510572A/ja not_active Withdrawn
- 2002-06-26 WO PCT/US2002/020565 patent/WO2003046185A1/en active Application Filing
- 2002-06-26 CA CA002468548A patent/CA2468548A1/en not_active Abandoned
- 2002-06-26 MX MXPA04005194A patent/MXPA04005194A/es not_active Application Discontinuation
-
2005
- 2005-11-08 HK HK05109969A patent/HK1078103A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714166A (en) * | 1986-08-18 | 1998-02-03 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates |
US5567410A (en) * | 1994-06-24 | 1996-10-22 | The General Hospital Corporation | Composotions and methods for radiographic imaging |
US6221959B1 (en) * | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
Non-Patent Citations (1)
Title |
---|
surface modifications of alginate/poly(10lysine) microcapsularmembranes with poly(ethylene glycol) and poly(vinyl alchohol) I.Ming Kung,biomaterials,Vol.16 No.8 1995 * |
Also Published As
Publication number | Publication date |
---|---|
HK1078103A1 (en) | 2006-03-03 |
CA2468548A1 (en) | 2003-06-05 |
WO2003046185A1 (en) | 2003-06-05 |
AU2002345981B2 (en) | 2007-11-01 |
US7060498B1 (en) | 2006-06-13 |
JP2005510572A (ja) | 2005-04-21 |
CN1617928A (zh) | 2005-05-18 |
EP1461436A4 (en) | 2006-03-22 |
MXPA04005194A (es) | 2005-06-20 |
AU2002345981A1 (en) | 2003-06-10 |
EP1461436A1 (en) | 2004-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1330765C (zh) | 聚阳离子水溶性共聚物和将聚阴离子大分子跨生物屏障传递的方法 | |
Van Bruggen et al. | Nonviral gene delivery with cationic glycopolymers | |
US7001891B1 (en) | Biodegradable polycation composition for delivery of an anionic macromolecule | |
KR100825519B1 (ko) | 키토산 기재 고분자 접합체 및 그 제조방법 | |
AU2015242970B2 (en) | Glycopolysialylation of non-blood coagulation proteins | |
CN108026527A (zh) | 确定的多偶联寡核苷酸 | |
KR101912978B1 (ko) | 페닐보론산기가 도입된 블록 공중합체 및 그의 용도 | |
US20030215395A1 (en) | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier | |
US20090068743A1 (en) | Cationic alpha-amino acid-containing biodegradable polymer gene transfer compositions | |
CN1281355A (zh) | 用于基因递送的生物可降解性混合聚合胶束 | |
CN101415444A (zh) | 生物可降解的阳离子聚合物 | |
JP6606490B2 (ja) | 二重誘導体化キトサンナノ粒子、並びに生体内での遺伝子導入のためのその製造、及び使用方法 | |
US20120130045A1 (en) | Biomolecule-polymer conjugates and methods of making same | |
JP5804453B2 (ja) | 結晶性ポリオール微粒子及びその調製方法 | |
CN106414749A (zh) | 用于胃肠给予rna的组合物 | |
CN110248665A (zh) | 具有降低的肾清除的多聚体寡核苷酸 | |
CN114716518A (zh) | 一种能够抑制pcsk9表达的分子构造及药物组合物 | |
JP2003231748A (ja) | 医用高分子及びその用途 | |
WO2012068870A1 (zh) | 三元复合物和含有三元复合物的液体及制备方法与应用 | |
US20200347385A1 (en) | METHOD FOR mRNA STABILIZATION | |
An et al. | Bioreducible crosslinked cationic nanopolyplexes from clickable polyethylenimines enabling robust cancer gene therapy | |
Prabu et al. | Biopolymer in gene delivery | |
WO2022163729A1 (ja) | 機能性核酸及びタンパク質導入用キャリア | |
JPH1045630A (ja) | 新規なグラフト共重合体、それを用いた薬剤、及びそれを用いて薬物を特定細胞に取り込ませる方法 | |
KR101958828B1 (ko) | 양이온성 작용기가 곁사슬 또는 말단에 도입된 폴리에틸렌글리콜/폴리에스터 블록 공중합체를 포함하는 생리활성물질 전달체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1078103 Country of ref document: HK |
|
CI01 | Correction of invention patent gazette |
Correction item: Address Correct: new jersey False: American Utah Number: 20 Volume: 21 Correction item: Applicant Correct: Genta Salus LLC False: Salus Therapeutics Number: 20 Volume: 21 |
|
CI02 | Correction of invention patent application |
Correction item: Address Correct: new jersey False: American Utah Number: 20 Page: The title page Volume: 21 Correction item: Applicant Correct: Genta Salus LLC False: Salus Therapeutics Number: 20 Page: The title page Volume: 21 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT ADDRESS; FROM: SALUS THERAPEUTICS UTAH, USA TO: GENTA SALUS LLC NEW JERSEY |
|
ERR | Gazette correction |
Free format text: CORRECT: APPLICANT ADDRESS; FROM: SALUS THERAPEUTICS UTAH, USA TO: GENTA SALUS LLC NEW JERSEY |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1078103 Country of ref document: HK |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |